- Home
- CTO vs PLRX Comparison
CTO vs PLRX Comparison
Compare CTO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- PLRX
- Stock Information
- Founded
- CTO 1902
- PLRX 2015
- Country
- CTO United States
- PLRX United States
- Employees
- CTO N/A
- PLRX N/A
- Industry
- CTO Real Estate Investment Trusts
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- PLRX Health Care
- Exchange
- CTO Nasdaq
- PLRX Nasdaq
- Market Cap
- CTO 589.6M
- PLRX 84.7M
- IPO Year
- CTO N/A
- PLRX 2020
- Fundamental
- Price
- CTO $17.69
- PLRX $1.29
- Analyst Decision
- CTO Strong Buy
- PLRX Hold
- Analyst Count
- CTO 3
- PLRX 10
- Target Price
- CTO $22.33
- PLRX $9.79
- AVG Volume (30 Days)
- CTO 372.4K
- PLRX 1.5M
- Earning Date
- CTO 07-29-2025
- PLRX 08-06-2025
- Dividend Yield
- CTO 8.59%
- PLRX N/A
- EPS Growth
- CTO N/A
- PLRX N/A
- EPS
- CTO N/A
- PLRX N/A
- Revenue
- CTO $132,203,000.00
- PLRX N/A
- Revenue This Year
- CTO $20.11
- PLRX N/A
- Revenue Next Year
- CTO $8.51
- PLRX N/A
- P/E Ratio
- CTO N/A
- PLRX N/A
- Revenue Growth
- CTO 17.48
- PLRX N/A
- 52 Week Low
- CTO $16.12
- PLRX $1.10
- 52 Week High
- CTO $21.15
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- CTO 45.36
- PLRX 43.30
- Support Level
- CTO $17.10
- PLRX $1.13
- Resistance Level
- CTO $17.71
- PLRX $1.43
- Average True Range (ATR)
- CTO 0.37
- PLRX 0.11
- MACD
- CTO -0.05
- PLRX -0.01
- Stochastic Oscillator
- CTO 53.80
- PLRX 37.57
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.